Federal Gov't Said to Claim Mylan (MYL) Overcharged Medicaid Over EpiPen
- Wall Street dips on Trump protectionism, Qualcomm drag
- Yahoo! (YHOO) Tops Q4 EPS by 4c; Sees Verizon Deal Closing in Q2, Not Q1
- Aetna's (AET) Humana (HUM) Takeover Blocked by Judge as Anticompetative
- Trump signs order withdrawing U.S. from Trans-Pacific trade deal
- After-Hours Stock Movers 1/23: (REXX) (MRCY) (SYNC) Higher; (FSM) (OCUL) (CASC) Lower (more...)
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Mylan (Nasdaq: MYL) shares are on watch following news that the Federal government is accusing the company of overcharging the Medicaid program by millions of dollars for its EpiPen product.
The WSJ noted commentary from Acting Administrator Andy Slavitt of the federal Centers for Medicare and Medicaid Services (CMS) in a letter on Wednesday.
Slavitt said Mylan incorrectly classified EpiPen as generic, when it should have been classified as brand name. That allow Mylan to pay a rebate of just 13%, or around $163 million, versus a rebate of 23.1 percent or more than it should've been paying.
Slavitt noted that the CMS has,
on multiple occasions provided guidance to the industry and Mylan on the proper classification of drugs and has expressly told Mylan that the product is incorrectly classified.
Shares of Mylan are flat Thursday morning.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Qualcomm (QCOM) Thrashed as Apple (AAPL) Lawsuit Threatens Licensing Business Model
- Endo Int'l (ENDP) Agrees to Abandon Noncompetitive Pay-for-Delay in Settlement with FTC
- Verizon Communications (VZ) on call put ratio of 1 call to 2.2 puts into Q4
Create E-mail Alert Related CategoriesLitigation, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!